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Abstract
Background: Anxiety disorders share common vulnerabilities and symptoms. Disorder-specific treatment is efficacious, but
few access evidence-based care. Administering transdiagnostic cognitive-behavioral therapy via the internet (iCBT) may
increase access to evidence-based treatment, with a recent randomized controlled trial (RCT) providing preliminary support
for this approach. This study extends those findings and aims to answer three questions: Is a transdiagnostic iCBT program
for anxiety disorders efficacious and acceptable? Does it result in change for specific disorders? Can good clinical outcomes
be obtained when guidance is provided via a Coach rather than a Clinician?
Method: RCT (N=131) comparing three groups: Clinician-supported (CL) vs. Coach-supported (CO) vs. waitlist control
(Control). Individuals met DSM-IV criteria for a principal diagnosis of generalized anxiety disorder (GAD), social phobia (SP) or
panic disorder with or without agoraphobia (Pan/Ag). Treatment consisted of an 8-lesson/10 week iCBT program with
weekly contact from a Clinician or Coach, and follow-up at 3-months post-treatment.
Results: Outcomes for the pooled treatment groups (CL+CO) were superior to the Control group on measures of anxiety,
depression and disability, were associated with medium to large effect sizes (Cohen’s d=.76 – 1.44) (response rate=89–
100%), and were maintained at follow-up. Significant reductions were found on disorder-specific outcomes for each of the
target diagnoses, and were associated with large effect sizes. CO participants achieved similar outcomes to CL participants
at post-treatment, yet had significantly lower symptom severity scores on general anxiety, panic-disorder, depression and
disability at follow-up (d=.45 – .46). Seventy-four percent of CO and 76% of CL participants completed the program. Less
than 70 minutes of Clinician or Coach time was required per participant during the program.
Discussion: This transdiagnostic iCBT course for anxiety appears to be efficacious, associated with significant change for
three target disorders, and is efficacious when guided by either a Clinician or Coach.
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Introduction
The anxiety disorders frequently co-occur and share similar
vulnerability factors and symptoms [1]. Disorder-specific treatment
protocols for anxiety are effective [2], however, less than 40% of
people with anxiety access mental health services [3]. There is
growinginterestinimproving accessand availabilityoftreatmentby
integrating low-intensity treatments, aimed at balancing minimal
intervention to maximum clinical gain, into routine care for
common mental disorders such as anxiety and depression [4,5].
Two innovative approaches that have the potential to improve the
proportion treated are Internet-delivered cognitive behavioral
therapy (iCBT) and transdiagnostic treatments.
iCBT programs teach the techniques of CBT in a highly
structured format and involve the delivery of online lessons with
remote support from a clinician. Meta-analyses of iCBT and
computerized CBT for anxiety disorders and depression indicate
that these treatments produce superior effect sizes over control
conditions and are comparable to face-to-face treatments [6,7,8].
Moreover, three studies compared clinical and non-clinical
support roles for guided iCBT and revealed no difference in
efficacy [9,10,11].
The second innovative approach is the use of transdiagnostic
protocols, also described as unified [12] or broad spectrum [13]
treatments. Transdiagnostic protocols can be considered as those
that apply treatment principles that are common to similar mental
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specific diagnosis to be effective [14,15,16]. While these protocols
have been created for the treatment of similar disorders, an
unresolved issue in this area concerns which disorders are suitable
for transdiagnostic treatment, particularly regarding PTSD and
OCD relative to other anxiety disorders [17]. Despite this, meta-
analyses of a relatively small number of studies indicate that face-to-
face transdiagnostic treatments may result in similar outcomes on
generic anxiety measures to disorder-specific treatments [16,18].
Evidence for the effectiveness of computer-delivered transdiag-
nostic treatments was provided by two early studies that used
computerized CBT to treat panic and phobias, and anxiety and
depression, demonstrating symptom reduction from single treat-
ment protocols [19,20]. These programs have now been integrated
within the UK Improved Access to Psychological Therapies
program, stepping consumers from low to high-intensity treat-
ments as clinically required, with completer analyses demonstrat-
ing good outcomes [4]. Additionally, preliminary support for the
efficacy of an internet-delivered transdiagnostic treatment was
reported in a recent RCT examining a transdiagnostic iCBT
program for generalized anxiety disorder (GAD), social phobia
(SP) and panic disorder (with or without agoraphobia) (Pan/Ag),
demonstrating reductions in anxiety, distress and disability [21].
The lessons in this program covered core components including
psychoeducation, cognitive restructuring, graded exposure, trou-
bleshooting common treatment difficulties and relapse prevention.
Additional resources covering issues such as low mood, improving
sleep and communication skills, were accessed by all participants
and were not prescribed. However, the sample size was not
sufficient to reliably examine whether changes occurred in
outcome measures for each of the three anxiety disorders.
The present study was an extension of the aforementioned study
[21], using a larger sample to explore a revised version of the
program, and also compared the relative benefits of Coach against
Clinician guidance. This study attempted to answer three
questions:
1. Is a transdiagnostic iCBT program for anxiety disorders
efficacious and acceptable?
2. Does the program result in change for each specific disorder?
3. Can good clinical outcomes be obtained when support is
provided by a Coach when compared with a Clinician?
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Design and objectives
The objectives were to determine (1) the efficacy of a
transdiagnostic iCBT program for anxiety disorders, (2) the
relative benefits to each of the target disorders, and (3) to compare
outcomes when the program is supported by either a Clinician or
Coach. The design comprised a CONSORT-R compliant RCT
comparing three parallel conditions: A Clinician-assisted iCBT
treatment group (CL group); a Coaching-assisted iCBT treatment
group (CO group); and a waitlist deferred-treatment control group
(Control).
Hypotheses
The three hypotheses were: 1) The pooled CL and CO group
(CL+CO) participants would show significant improvement on
general and disorder-specific measures of anxiety, and measures of
depression and disability after treatment, relative to Control
participants, and would rate the treatment as acceptable; 2) the
pooled CL+CO participants would show significant improvement
on disorder-specific measures of anxiety over time, and; 3)
participants in the CO group would achieve at similar outcomes
to the CL group across all measures and time points.
Ethics
The study was approved by the Human Research Ethics
Committee (HREC) of St Vincent’s Hospital (Sydney, Australia)
and the HREC of the University of New South Wales (Sydney,
Australia). All participants provided written informed consent.
The trial was registered as ACTRN12610000242022.
Participants
Potential participants consisted of individuals who had previ-
ously expressed interest in treatment via the online programs
available on a research website, or from visitors to the website.
Applicants applied online to the research website where they read
details about the study. Details of participant flow are in Figure 1.
During the 4 weeks of recruitment in early 2010, 253 individuals
applied and 139 met the following inclusion criteria: (i) resident of
Australia; (ii) at least 18 years of age; (iii) access to a computer, the
Internet, and use of a printer; (iv) not currently participating in
CBT; (v) not using illicit drugs or consuming more than three
standard drinks a day; (vi) not currently experiencing a psychotic
mental illness or severe symptoms of depression (defined as a total
score .22 or responding .2 to Question 9 (suicidal ideation) on
the Patient Health Questionnaire - 9 Item [22]; (vii) if taking
medication (people taking benzodiazepines were excluded), had
been taking the same dose for at least 1 month and did not intend
to change that dose during the course of the program; and (viii)
met DSM-IV [23] diagnostic criteria for a principal diagnosis
(defined as the disorder the participant nominated as most
troubling) of GAD, SP, or Pan/Ag. Applicants who did not meet
these criteria were informed via an on-screen message and were
sent an email thanking them for their application and encouraging
them to discuss their symptoms with their physician. Participants
who met the inclusion criteria then completed a 25-item
questionnaire enquiring about demographic details and treatment
history (see Table 1).
Applicants who passed the screening phase were telephoned and
administered a diagnostic interview using the Mini International
Neuropsychiatric Interview Version 5.0.0 (MINI) [24] to deter-
mine whether they met DSM-IV criteria [23] for GAD, SP or
Pan/Ag. Applicants who satisfied all criteria and completed a
consent form were included in the study.
Interventions
Both treatment groups received access to the Anxiety Program
[21]. The intervention used in the present study employed a
version with the following changes: i) information about cognitive
skills were presented in the second rather than third lesson; ii) two
new lessons were added to address core beliefs, beliefs about
anxiety, and assertive communication and interpersonal bound-
aries; iii) the duration of the program was increased from eight to
ten weeks. The enhanced Anxiety Program comprised the
following components: Eight online lessons; a summary/home-
work assignment for each lesson; weekly telephone or email/
asynchronous messaging contact with the Clinician or Coach, and
regular automated reminder and notification emails. All partici-
pants also had access to additional written resources that included
guidelines about managing low mood, improving sleep, and
RCT of Transdiagnostic Internet CBT for Anxiety
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doi:10.1371/journal.pone.0028079.g001
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skills described in the lessons and summaries, although these were
not prescribed as per other treatment protocols [25]. Participants
were also provided with access to de-identified vignettes written by
participants in previous iCBT programs covering topics relevant to
each of the eight lessons. The content of each lesson is described in
Table 2.
Each Lesson began with a restatement of the key skills described
in previous lessons, an introduction to skills described in the
current lesson, illustrated examples about people with each of the
target disorders practicing those skills, and a summary of the main
points. Participants were encouraged to complete one lesson each
week, to complete the recommended homework and to complete
the eight lessons within 10 weeks.
Clinician/Coach roles
Two staff conducted the study with supervision from NT. The
Clinician role was fulfilled by JS who had completed specialist
post-graduate training in Clinical Psychology, had 2.5 years post-
clinical training experience, had previously treated participants
using iCBT in two other trials [9,21], and was employed as a
Clinical Psychologist at the Anxiety Disorders Clinic, St Vincent’s
Hospital Sydney. The Coach role was performed by LJ, a
Registered Psychologist without specialist post-graduate training,
employed as a Research Assistant at the same research unit.
Clinician and Coach roles performed specific and distinct
functions. Both roles required strict adherence to a pre-determined
script to be followed throughout all contact with participants that
specified: Reinforcing progress to date; encouraging the comple-
tion of further lessons; encouraging practice of homework tasks;
normalising difficulties with practicing homework tasks; and
providing direction to upcoming materials. In the event of
receiving clinical questions the Coach was instructed to direct
the participant to the program content or inform of upcoming
materials that would address the question. The Coach was not
permitted to provide clinical advice or to elaborate, expand upon
Table 1. Demographic characteristics of the Coach assisted, Clinician assisted and Control groups.
CO Group CL Group Control Group Total Statistical significance
Variable n % n % n % n %
Gender
Male 15 34.9 23 50.0 16 38.1 54 41.2 X2(2,N=131)=2.35,
p=0.31
Female 28 65.1 23 50.0 26 61.9 77 58.8
Age
Mean 38.63 (11.56) - 43.74 (13.36) - 42.36 (13.20) - 41.62 (12.83) - F2,128=1.89, p=0.16
Range 19-59 - 20-69 - 21-79 - 19–79 -
Marital Status
Single/Never Married 13 30.2 12 26.1 14 33.3 39 29.8 X2(4, N=131)=5.29,
p=0.26
Married/De Facto 26 58.1 20 43.5 20 47.6 65 49.6
Separated/Divorced 5 11.6 14 30.4 8 19.0 27 20.6
Education
High school 10 23.3 8 17.4 7 16.7 25 19.1 X2(6, N=131)=5.48,
p=0.48
Tertiary 29 67.4 30 65.2 25 59.5 84 64.1
Other Certificate 4 9.3 7 15.2 10 23.8 21 16.0
None 0 0.0 1 2.2 0 0 1 .8
Employment Status
Part time/student 19 44.2 14 30.4 19 36.5 52 39.7 X2(4,N=131)=2.63,
p=0.62
Full time 18 41.9 23 50.0 17 40.5 58 44.3
Unemployed, retired or disabled 6 14.0 9 19.6 6 14.3 21 16.0
Previously Mental
Health Treatment
29 67.4 32 69.6 31 73.8 92 70.2 X2(2, N=131)=0.43,
p=0.81
Taking Medication 11 25.6 18 39.1 9 21.4 38 29.0 X2(2, N=131)=3.71,
p=0.16
Contact During Program Mean SD Mean SD Mean SD
Number of phone calls 7.56 1.19 7.54 2.43 - - - - t87=.32, p=0.98
Number of manual written contacts 8.88 4.38 8.83 3.19 - - - - t87=.87, p=0.94
Number of automated written contacts 19.37 1.75 20.43 3.50 - - - - t87=.21.79, p=0.08
Total contact time (min) 69.09 30.75 69.59 32.29 - - - - t87=2.07, p=0.94
doi:10.1371/journal.pone.0028079.t001
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program. The Clinician, however, was invited to provide therapy
and engage the participant in more detailed discussion of the
materials including how to apply the treatment, to provide further
detail about the skills, assist the participant in practicing those
skills, and suggest additional skills if applicable. Both Clinician and
Coach received weekly supervision from an independent clinical
psychologist (NT) as a matter of routine professional and ethical
care. These sessions allowed discussion of clinical issues, and the
opportunity for the Coach to refer participants to the Clinician in
the event of any perceived deterioration in the participants’ mental
health status, or of any concerns about participants’ wellbeing.
Supervision was also provided to reinforce adherence to the script
and guidelines and ensure that the Coach did not attempt
‘therapy’. Both Clinician and Coach were advised to limit weekly
contact time to approximately 10 minutes per participant, unless
more time was clinically indicated. Every instance of contact with
each participant was recorded as was the total time that the
Clinician and Coach spent per participant.
Outcomes
A wide range of measures were used. The total number of
questionnaire items was kept below 80 to reduce burden on
participants. The Mini International Neuropsychiatric Interview
Version 5.0.0 (MINI) [24] was used as a diagnostic measure. The
Generalized Anxiety Disorder 7-Item Scale, (GAD-7) [26] and
Depression Anxiety Stress Scales – 21 Item (DASS-21) [27] were
used as primary outcome measures. The Penn State Worry
Questionnaire (PSWQ) [28], Social Interaction Anxiety Scale and
Social Phobia Scale – Short Form (SIAS-6/SPS-6) [29] and Panic
Disorder Severity Scale – Self Rating (PDSS-SR) [30] were used as
disorder-specific outcome measures. The Patient Health Ques-
tionnaire – 9 Item (PHQ-9) [22] and Sheehan Disability Scales
(SDS) [31] were used as secondary outcome measures. Each of
these measures will be discussed in detail below.
Mini International Neuropsychiatric Interview Version
5.0.0 (MINI) [24]. The MINI is a brief diagnostic interview
developed to determine the presence of current and lifetime Axis-I
disorders using DSM-IV diagnostic criteria and was chosen in
favour of other diagnostic interviews to reduce participant burden.
Psychometric evaluations of the MINI [32] indicate it has excellent
inter-rater reliability (k=.88 – 1.00) and adequate concurrent
validity with the Composite International Diagnostic Interview.
Pre-treatment interviews were conducted by LJ and JS. Three-
month follow-up interviews were conducted by LJ, JS and BD.
Generalized Anxiety Disorder 7-Item Scale, (GAD-7)
[26]. The GAD-7 comprises seven items measuring symptoms
and severity of GAD based on the DSM-IV diagnostic criteria for
GAD. The GAD-7 has good internal consistency (.89) and good
convergent validity with other anxiety scales [33]. Evidence
indicates the GAD-7 is sensitive to GAD, social phobia, and panic
disorder with increasing scores indicating greater severity of
symptoms [34]. The GAD-7 is increasingly used in research and in
large scale dissemination studies as a generic measure of change in
anxiety symptoms [4,35]. The internal consistency of the GAD-7
in the current study was high (Cronbach’s a=.86).
Depression Anxiety Stress Scales – 21 Item (DASS-21)
[27]. The DASS-21 is a measure of severity of symptoms for
anxiety, stress, and depression, and is used to measure change in higher-
order, or common symptoms across anxiety and depressive disorders. It
comprises three subscales that assess features uniquely associated with
d e p r e s s i o n ,a n x i e t y ,a n dp s y c h o l o g ical distress. The 21-item short form
has demonstrated excellent psychometric properties including good
internal consistency and concurrent validity comparable with the
original 42-item measure [36]. The internal consistency of the DASS-21
in the current study was high (Cronbach’s a=.88).
Penn State Worry Questionnaire (PSWQ) [28]. The
PSWQ consists of 16 items and is considered a valid clinical
measure of worry characteristic of GAD. Early psychometric
evaluations revealed the PSWQ had high internal consistency and
temporal stability [28], and was able to differentiate patients with
GAD from those with other anxiety disorders [37]. The internal
consistency (Cronbach’s a) of the PSWQ in the current study was
.90.
Table 2. Content of the Anxiety Program.
Lesson Primary content/theme Secondary content/theme De-identified vignettes
1 Education about the prevalence, symptoms and
treatment of anxiety including an explanation
of the functional relationship between symptoms
Examples describing symptoms
Normalising difficulties during recovery
Examples of symptoms and their
impact, and outlook on treatment
2 Basic principles of cognitive therapy, including
strategies for monitoring and challenging
thoughts, and structured problem solving
Providing examples of unhelpful thoughts
and examples of challenges to thoughts
3 Instructions about controlling physical
symptoms including de-arousal strategies
and scheduling activities
The importance of lifestyle factors Examples of using de-arousal strategies i
ntroducing lifestyle changes
4 Education and guidelines about
practicing graded exposure
Normalising difficulties with exposure and
creating realistic treatment goals
Providing examples of exposure tasks
5 Education and guidelines about advanced
cognitive skills including belief challenging
Consolidating thought challenging tasks Normalising distressing beliefs, examples of the
impact of successfully challenging beliefs
6 Education and guidelines for acting
‘‘as if’’ and troubleshooting common
barriers to treatment
Reporting examples of hurdles or barriers to
treatment and attempts at overcoming these
7 Education and guidelines surrounding
assertive communication and
interpersonal boundaries
Communication skills Examples of how communication styles and
interpersonal boundaries contribute
to anxiety, and can be managed
8 Information about relapse prevention
and constructing relapse prevention plans
Relapse prevention plan and reviewing
key skills from program
doi:10.1371/journal.pone.0028079.t002
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Short form (SIAS-6/SPS-6) [29]. The SIAS-6/SPS-6 is a
recently developed brief measure of social anxiety (12 items) based
on the items of the Social Interaction Anxiety Scale (SIAS) and the
Social Phobia Scale (SPS) [38]. The measure correlated strongly
and significantly with the SIAS and SPS in clinical samples at pre-
treatment, post-treatment, and at 3-month follow-up (rs=.79 –
.90), and also correlated strongly and significantly with change
scores in the SIAS and SPS following treatment (rs=.81 –.91).
Cronbach’s a of the SIAS-6/SPS-6 in the current study was .92.
Panic Disorder Severity Scale – Self Rating (PDSS-SR)
[30]. The PDSS-SR is a seven-item measure of panic disorder
severity. Psychometric evaluations suggest it has excellent
psychometric properties including high internal consistency
(Cronbach’s a=.92), good test-retest reliability (r=.81), and
sensitivity to change [30]. Cronbach’s a of the PDSS-SR in the
current study was high (.92).
Patient Health Questionnaire – 9 Item (PHQ-9) [22]. The
PHQ-9 is a nine-item measure of the symptoms and severity of
major depressive disorder based on the DSM-IV criteria for
depression. A total score of 10 on the PHQ-9 has also been
identified as an important threshold for identifying DSM-IV
congruent depression with increasing scores indicating greater
symptom severity [22]. Psychometric studies indicate the internal
consistency is high (.86 – .89) [22] and the measure is sensitive to
change [33]. The internal consistency of the PHQ-9 in the current
study was high (Cronbach’s a=.84).
Sheehan Disability Scales (SDS) [31]. The SDS comprises
three items measuring impairment in psychosocial functioning
with high internal consistency (a=.89) [39]. The internal
consistency (Cronbach’s a) of the SDS in the current study was
.83.
With the exception of the SIAS-6/SPS-6, which is still under
evaluation, all of these measures are considered reliable, valid, and
appropriate for clinical research purposes. Moreover, recent
research indicates that online administration of questionnaires
results in acceptable reliability of responses with emerging
evidence for equivalence between paper-and-pencil versions of
self-report questionnaires and online administration [40,41,42,43].
At post-treatment, all participants also completed a 7-item
treatment satisfaction questionnaire based on the Credibility/
Expectancy Questionnaire (CEQ) [44]. Additional questions
enquiring about treatment satisfaction with the transdiagnostic
treatment protocol were administered to participants in the
treatment groups at follow-up. All questionnaires were adminis-
tered via the Internet.
Timepoints
All participants were asked to complete the questionnaire
outcome measures (GAD-7, DASS-21, PSWQ, SIAS-6/SPS-6,
PDSS-SR, PHQ-9 and SDS) at pre-treatment, post-treatment,
and at 3-month follow-up. Control group participants began
treatment immediately after the CL and CO post-treatment time
point, so the 3-month follow up for the CL and CO groups
coincided with the post-treatment time point for the Control
group.
Sample size and randomization
Power calculations indicated that a sample size of 36
participants in each group was sufficient to detect an effect size
(ES) difference of 0.6 between the treatment groups and the
Control group, with alpha at .05 and power of 80%, which was the
minimum expected based on similar studies [9,45,46]. The study
was not powered to detect small differences between the treatment
groups.
One-hundred and thirty-nine applicants met all inclusion
criteria and were randomized via a true randomization process
(www.random.org), generated by an independent person, to either
CL, CO or Control groups. The allocation sequence preceded
pre-treatment diagnostic interviews and was concealed from LJ
and JS. Researchers completing 3-month follow-up interviews
were not blind to group allocation. Dependence on self-report
measures precluded blinding.
Statistical analyses
Analysis of primary, disorder-specific and secondary
outcome measures. Baseline between-group differences in
demographic data and pre-treatment measures were analysed
with one-way ANOVAs and chi-square tests. To determine whether
the transdiagnostic iCBT program was efficacious, scores from the
CL and CO groups were pooled to create a single CL+CO group.
To explore the relative clinical outcomes of each type of support,
CL and CO data were analysed separately.
All post-treatment and 3-month follow-up analyses involved an
intention-to-treat (ITT) design and missing data was addressed by
carrying forward the first available data (baseline-observation-
carried-forward; BOCF). Between-group changes in questionnaire
scores were analysed using univariate ANCOVAs, assigning pre-
treatment scores as the covariate. This approach is recommended
as a robust and reliable statistical strategy for analysing the results
of RCTs [47,48]. Independent-samples t-tests were used to assess
between-groups differences in the number and duration of
contacts with participants. Within-group changes in questionnaires
were analysed using paired-samples t-tests. Effect sizes (Cohen’s d)
were calculated for within- and between-group changes, based on
the pooled standard deviation.
Clinical significance. Two criteria of clinical significance
were employed. Pre-treatment, post-treatment and 3-month follow
up GAD-7 scores were compared with clinical cut-offs to provide
an index of remission. This was defined as the proportion of
participants who initially scored at or above, and subsequently
scored below the cut-offs of a GAD-7 total score $8 [34]. An
estimate of recovery was made by identifying the proportion of
participants in each group who scored above the aforementioned
pre-treatment threshold and subsequently demonstrated a
significant reduction in their symptoms (defined here, as a
reduction of 50% of pre-treatment GAD-7), as described in
recent dissemination studies [4]. Secondly, changes in prevalence
of principal and additional disorders of anxiety in the two
treatment groups were calculated on the results of the diagnostic
interviews conducted at pre-treatment and 3-month follow-up and
were analysed with chi-square tests. All quantitative analyses were
performed in PASW version 18.0 (SPSS, Inc., Chicago, IL).
Control group results. As a preliminary test of the reliability
of outcome associated with the Coach condition, data from the
Control group, following their treatment, is reported.
Results
Participant flow
Two hundred and fifty-three individuals expressed interest in
the study, and 139 met the eligibility criteria and were randomized
to one of the three groups. One CO group and four Control group
participants withdrew before beginning the program. Additionally,
two CO group and one CL group participant withdrew before
beginning treatment, which resulted in 43 CO, 46 CL and 42
Control group participants eligible for analysis (see Figure 1).
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Table 1 shows the demographic characteristics of each group
and the overall sample. There were no significant between-group
differences in gender, marital status, education, employment,
previous discussions of symptoms with a health professional, use of
medication (X2 range(2–6, N=131)=0.76 – 8.60, p range=.15 –
.69), age or treatment expectancy (F2, 128 range=.62 – 1.89, p
range=.15 – .51).
Principal and additional diagnoses are displayed in Table 3.
Twenty-nine of 43 (67%) CO, 35/46 (76%) CL and 28/42 (67%)
Control participants had a co-morbid anxiety or depressive
disorder (70% of the overall sample). At pre-treatment, GAD
was the most common principal disorder followed by SP and Pan/
Ag. There were no statistically significant differences between
groups in the prevalence of each principal diagnosis, or the
presence of additional diagnoses (X2(2–4, N=131) range=1.09 –
1.17, p range=.56 – .90).
Table 4 shows the pre-treatment scores for the pooled CL+CO
group and for the Control group, and Table 5 shows the pre-
treatment scores for the CO and CL groups separately, on
primary, disorder-specific and secondary outcome measures.
There was a trend towards significance between groups in pre-
treatment scores on the DASS-21 (F2, 128=2.83, p=.06), and no
significant differences between CO, CL and Control groups in
pre-treatment scores on the GAD-7, PSWQ, PDSS-SR, SIAS-6/
SPS-6, PHQ-9 or SDS (F2, 128 range=.07 – .79, p range=.45 –
.94).
Adherence and attrition
Thirty-two of 43 (74%) CO and 35/46 CL (76%) group
participants completed all eight lessons within the 10-week
program. A further four (9%) CO participants completed the
remaining lesson within seven days of the Program ending, but no
CL participants completed within that time frame. There was no
difference (t87=1.10, p=.27) in the mean number of lessons
completed by CO group (7.57; SD=0.99) and CL group
participants (7.09; SD=1.81). Post-treatment data was collected
from 39/43 (90%) CO, 41/46 (89%) CL, and from 42/42 (100%)
Control group participants. Three month follow-up data was
provided by 40/43 (93%) CO and 34/46 (74%) CL group
participants.
Is a transdiagnostic iCBT program for anxiety disorders
efficacious?
Univariate ANCOVAs, controlling for pre-treatment scores, on
post-treatment primary, disorder-specific and secondary outcomes
outcome measures (Table 4) revealed significant differences
between CL+CO and Control groups on the GAD-7, DASS-21,
PSWQ, SIAS-6/SPS-6, PDSS-SR, PHQ-9, and SDS (F2,
130=28.28 – 53.68, p,.000). Paired samples t-tests revealed no
significant difference between post-treatment and 3-month follow
up scores for the CL+CO group (t88=21.15 – 2.13, p=.13 – 99).
Between- and within-group effect sizes on primary measures are
included on Table 4. Large between-group effect sizes were
achieved by the CL+CO group relative to the Control group on
the GAD-7, DASS-21, PSWQ, SIAS-6/SPS-6, PDSS-SR and
PHQ-9, (d=.81 – 1.44) and a moderate effect size was found on
the SDS (d=.76). Large within group effect sizes were achieved by
the CL+CO group at post-treatment on the GAD-7, DASS-21,
PSWQ, PHQ-9 and SDS (d=.85 – 1.28), and a moderate effect
size was achieved on the SIAS-6/SPS-6, and PDSS-SR (d=.76
and d=.71, respectively). The within-group effect sizes appeared
stable through to 3-month follow-up.
At pre-treatment, 71/89 (80%, 95% CI (70–87%) CL+CO
participants scored above the cutoff for the GAD-7 (total score
$8). At post-treatment 46/71 (65%, 95% CI (53–75%) met
Table 3. Frequency of principal diagnoses and comorbidity for Treatment and Control groups at pre-treatment, and 3-month
follow up for CO and CL groups.
Pre-treatment 3-month follow-up
CO Group CL Group Control Group Total CO Group CL Group Total
N% N% N% N % N% N% N%
Principal diagnosis
GAD 18 41.9 21 45.7 20 47.6 59 45.0 7 16.3 9 19.6 16 18.0
SP 14 32.6 16 34.8 15 35.7 45 34.4 5 11.6 11 23.9 16 18.0
Pan/Ag 11 25.6 9 19.6 7 25.9 27 20.6 5 11.6 6 13.0 11 12.8
Comorbid condition
None 14 32.7 11 23.9 14 33.3 39 29.8 35 81.4 26 56.5 61 68.5
Anxiety only 13 30.2 14 30.4 11 26.2 38 29.0 3 7.0 11 23.9 14 15.7
Affective only 3 7.0 7 15.2 2 4.8 12 9.2 1 2.3 1 2.2 2 2.2
Anxiety and affective only 13 30.2 14 30.4 15 35.7 42 32.1 4 9.3 8 17.4 12 13.5
Number of additional
diagnoses
0 14 32.6 11 23.9 14 33.3 39 29.8 35 81.4 26 56.5 61 68.5
1 13 30.2 17 37.0 9 21.4 39 29.8 4 9.3 7 15.2 11 12.4
2 8 18.6 11 23.9 13 31.0 32 24.4 1 2.4 10 21.7 11 12.4
3+ 8 18.6 7 15.2 6 14.3 21 16.0 3 7 3 6.5 6 6.7
Note: Intention-to-treat model was employed with pre-treatment diagnoses being carried forward if follow-up data was not available. Diagnostic interviews were not
repeated with Control group as they had begun treatment. Abbreviations: GAD, Generalised Anxiety Disorder; SP, social phobia; Pan/Ag, panic disorder with or without
agoraphobia; CO: Coach-assisted; CL: Clinician-assisted.
doi:10.1371/journal.pone.0028079.t003
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95% CI (39–62%) met criteria for recovery (GAD-7 total score ,7
and reduction of at least 50% in total score). At 3-month follow up,
45/71 (63%, 95% CI (52–74%) met criteria for remission and 37/
71 (52%, 95% CI (70–87%) met criteria for recovery. Addition-
ally, at 3-month follow-up, 46/89 (52%, 95% CI (41–62%) of the
CL+CO group no longer met diagnostic criteria for a principal
diagnosis of GAD, SP or Pan/Ag (Table 3). Chi square tests
demonstrated a significant reduction from pre-treatment to 3-
month follow-up in the number of participants meeting criteria for
GAD (X2(1, N=178)=13.92, p,.05), SP (X2(1, N=178)=5.75,
p,.05), and a non-significant reduction regarding Pan/Ag (X2(2,
N=178)=3.16, p=.08).
Thirty-seven of 43 (86%) CO and 40/46 (87%) CL group
participants completed post-treatment satisfaction questionnaires.
Results for the two groups were pooled as there were no significant
differences in satisfaction ratings (X2(2, N=78)=4.81, p=.09).
Sixty-five of seventy-seven (84%) CL+CO group participants
responded to the satisfaction questionnaire and reported that they
were either very or mostly satisfied with the Program. An additional
12/77 (16%) participants reported they were neutral/somewhat
dissatisfied with the Program, but no participants reported they
were very dissatisfied with the Program. Additionally, 75/77 (97%)
participants said they would feel confident in recommending the
Program to a friend.
Does the program result in change in each specific
disorder?
Pre-treatment, post-treatment, and 3-month follow-up data for
the pooled CL+CO group by principal disorder is presented in
Table 6. Pre to post-treatment paired sample t-tests revealed
significant improvements in PSWQ, SIAS-6/SPS-6 and PDSS-SR
scores, regardless of principal diagnosis (t range 19-38=3.65 – 9.13,
p,.000). Importantly, these analyses were significant when
adjusting for the multiple comparisons required to examine this
effect across the nine questionnaire measures (p significance
level=.005). Paired sample t-tests revealed no change on the
PSWQ, PDSS-SR, or SIAS-6/SPS-6 from post-treatment to 3-
month follow up for any of the three principal diagnoses (t range 19-38=
.11 – 1.53, p=0 . 1 4–. 9 1 ) .
Participants with a principal diagnosis of GAD, SP or Pan/Ag
achieved large within-group effect sizes on their corresponding
disorder-specific measure (Table 6). Additionally, participants
achieved small to large effect sizes on disorder-specific measures
that did not correspond to their principal diagnosis. These gains
were generally stable at 3-month follow-up.
Can good clinical outcomes be obtained when support is
provided by a Coach?
Pre-treatment, post-treatment and 3-month follow up data for
the CO and CL groups is presented in Table 5. Univariate
Table 4. Means, standard deviations and effect sizes (Cohen’s d) for pooled CL+CO and Control groups on all outcome measures
at pre-treatment, post-treatment and 3-month follow-up time points.
Measure and group
Pre-treatment
Mean
Post-treatment
Mean Follow-up Mean Within-group effect size Between-group effect size
Pre- to post-
treatment
Pre-treatment to
follow-up Post-treatment
GAD-7
CL+CO (n=89) 11.71 (4.34) 6.17 (4.38) 6.61 (5.54) 1.28 (.38 – 2.19) 1.03 (.13 – 2.18) 1.44 (.05 – 2.31)
Control (n=42) 12.50 (4.80) 11.79 (4.60) 5.70 (3.53) 0.15 (21.30 – 1.54) 1.63 (.18 – 2.70) -
DASS-21
CL+CO (n=89) 50.70 (21.75) 28.67 (21.71) 27.35 (25.14) 1.02 (23.50 – 5.53) 1.00 (23.52 – 6.22) .94 (25.24 – 5.45)
Control (n=42) 52.57 (20.86) 48.48 (20.41) 24.25 (16.54) 0.20 (26.11 – 6.37) 1.52 (24.79 – 6.52) -
PSWQ
CL+CO (n=89) 63.63 (11.01) 52.07 (10.70) 52.06 (13.37) 1.07 (21.22 – 3.29) .95 (21.34 – 3.73) .83 (23.02 – 3.06)
Control (n=42) 61.29 (12.66) 61.50 (12.74) 50.05 (11.23) 0.02 (23.85 – 3.84) 0.95 (22.85 – 4.35) -
SIAS-6/SPS-6
CL+CO (n=89) 20.31 (11.45) 12.56 (9.03) 13.26 (10.53) .76 (21.62 – 2.63) 0.64 (21.73 – 2.83) .89 (23.30 – 2.76)
Control (n=42) 22.17 (13.59) 22.05 (13.83) 14.53 (11.10) 0.01 (24.10 – 4.19) 0.62 (23.49 – 3.98) -
PDSS-SR
CL+CO (n=89) 10.20 (6.89) 5.71 (5.80) 5.97 (7.31) .71 (2.72 – 1.91) .60 (2.83 – 2.12) .81 (21.11 – 2.01)
Control (n=42) 10.74 (6.44) 10.50 (6.35) 5.58 (5.03) 0.04 (21.91 – 1.96) 0.90 (21.05 – 2.46) -
PHQ-9
CL+CO (n=89) 11.46 (5.57) 6.88 (5.21) 6.76 (6.00) .85 (2.30 – 1.94) .82 (2.34 – 2.06) .85 (2.75 – 1.93)
Control (n=42) 11.71 (6.31) 11.29 (5.28) 11.29 (5.28) 0.07 (21.84 – 1.67) 0.88 (21.03 – 2.42) -
SDS
CL+CO (n=89) 17.17 (7.06) 10.15 (7.54) 9.27 (8.82) .97 (2.50 – 2.53) .99 (2.47 – 2.83) .76 (21.58 –2.33)
Control (n=42) 16.43 (7.74) 15.88 (7.75) 9.40 (7.71) 0.07 (22.27 – 2.42) 0.92 (21.42 – 3.25) -
Note. The standard deviations of the means and the confidence intervals of effect sizes are shown in parentheses. Intention-to-treat model was employed with pre-
treatment scores being carried forward if post-treatment or follow-up data was not available Abbreviations: GAD-7: Generalized Anxiety Disorder 7-Item; DASS-21:
Depression Anxiety Stress Scales-21 item; PSWQ: Penn State Worry Questionnaire; SIAS-6/SPS-6: Social Interaction Scale and Social Phobia Scale Short Form; PDSS-SR:
Panic Disorder Severity Scale – Self Rating; PHQ-9: Patient Health Questionnaire-9 item; SDS: Sheehan Disability Scale. CO: Coach-assisted; CL Clinician-assisted.
doi:10.1371/journal.pone.0028079.t004
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group had significantly lower GAD-7 scores, and a trend towards
significantly lower DASS-21 scores, than the CL group at post-
treatment (F1,88=5.37, p=.02, F1,88=3.85, p=.05, respectively).
There was no significant difference between CO and CL groups
on PSWQ, SIAS-6/SPS-6, PDSS-SR, PHQ-9 and SDS at post-
treatment (F1, 88=1.0 – 3.72, p=.06 – 32).
Univariate ANCOVAs controlling for pre-treatment scores
revealed the CO group had significantly lower GAD-7, PDSS-SR,
PHQ-9, and SDS scores than the CL group at 3-month follow up
(F1, 88=5.11 – 7.71, p=.007 – .03), but no difference on the
DASS-21, PSWQ, SIAS-6/SPS-6, (F1, 88=1.85 – 2.94, p=.09 –
.18). Paired samples t-tests revealed no significant change from
post-treatment to 3-month follow up on any measure for either
CO (p range=.69–1.0) and CL (p range=.25–.48) groups.
Between- and within-group effect sizes on primary, disorder-
specific measures, and measures of depression and disability are
included in Table 5. Small to medium (d=.20 –.62) between-
group effect sizes were achieved by the CO group relative to the
CL group on all measures at post-treatment and 3 month-follow-
up. Large within-group effect sizes were achieved by the CO
group on all measures at post-treatment (d=.80 – 1.29). At post-
treatment, the CL group achieved large within group effect sizes
on the DASS-21, PSWQ, and SDS (d=.81 – .90), and moderate
effect sizes on the GAD-7, SIAS-6/SPS-6, PDSS-SR, and PHQ-9
(d=.67 – .71). These gains appeared generally stable at 3-month
follow-up.
Contact Events
Table 1 displays the frequency of contact events and duration of
total contact time per participant. No significant differences were
observed between the CO and CL groups in the number of phone
calls, manually written contacts, automated written contacts or the
total contact time provided by the Coach and Clinician
throughout the program (t87 range=21.79 – .87, p range=.08
– .98).
Control group results
As a partial replication of the CO condition, Control group
participants received weekly support from the Coach during their
treatment phase, consistent with that provided to the original CO
group. One Control group participant withdrew before beginning
the active treatment phase of the program reporting their
symptoms had sufficiently resolved, and another could not be
contacted, resulting in 40 Control group participants commencing
the active treatment phase of the Anxiety program and eligible for
analysis. Of these, 33 (82.5%) participants completed the eight
lessons within the ten weeks of the program, and an additional two
Table 5. Means, standard deviations and effect sizes (Cohen’s d) for CO and CL groups on all outcome measures at pre-treatment,
post-treatment and 3-month follow-up timepoints.
Measure
and group
Pre-treatment
Mean
Post-treatment
Mean Follow-up Mean Within group effect size Between group effect size
Pre- to post-
treatment
Pre-treatment to
follow-up Post-treatment Follow-up
GAD-7
CO (n=43) 11.28 (5.18) 6.16 (4.59) 5.37 (4.98) 1.06 (20.49 – 1.06) 1.18 (20.37 – 2.67) 0.27 (21.38 – 1.64) 0.46 (21.45 – 1.95)
CL (n=46) 11.63 (5.96) 7.54 (5.70) 8.07 (6.61) 0.71 (21.01 – 2.36) 0.57 (21.15 – 2.48) - -
DASS-21
CO (n=43) 45.30 (19.54) 22.05 (16.90) 21.16 (22.27) 1.29 (24.55 – 6.34) 1.17 (24.67 – 7.82) 0.62 (26.30 – 5.67) 0.49 (27.16 – 7.15)
CL (n=46) 55.74 (22.69) 34.87 (23.95) 33.13 (26.49) 0.90 (25.65 – 7.83) 0.93 (25.63 – 8.58) - -
PSWQ
CO (n=43) 62.81 (11.35) 50.28 (10.34) 49.86 (12.00) 1.17 (22.22 – 4.26) 1.12 (22.27 – 4.71) 0.52 (22.62 – 3.65) 0.33 (23.82 – 3.96)
CL (n=46) 64.39 (10.75) 53.74 (10.86) 54.19 (14.37) 0.81 (22.30 – 3.95) 0.81 (22.39 – 4.97) - -
SIAS-6/
SPS-6
CO (n=43) 19.95 (12.84) 10.95 (8.98) 11.65 (9.64) 0.82 (23.02 – 3.51) 0.74 (23.10 – 3.62) 0.35 (22.22 – 3.04) 0.30 (22.94 – 3.18)
CL (n=46) 20.65 (10.12) 14.07 (8.90) 14.76 (11.20) 0.70 (22/23 – 3.27) 0.56 (22.37 – 3.79) - -
PDSS-SR
CO (n=43) 9.72 (6.89) 4.95 (4.99) 4.30 (6.68) 0.80 (21.26 – 2.29) 0.81 (21.25 – 2.80) 0.26 (21.61 – 1.75) 0.45 (21.74 – 2.45)
CL (n=46) 10.65 (6.93) 6.41 (6.44) 7.52 (7.59) 0.67 (21.19 – 2.53) 0.45 (21.40 – 2.64) - -
PHQ-9
CO (n=43) 11.28 (5.18) 6.16 (4.59) 5.37 (4.98) 1.06 (20.49 – 1.06) 1.18 (20.37 – 2.67) 0.27 (21.38 – 1.64) 0.46 (21.45 – 1.95)
CL (n=46) 11.63 (5.96) 7.54 (5.70) 8.07 (6.61) 0.71 (21.01 – 2.36) 0.57 (21.15 – 2.48) -
SDS
CO (n=43) 16.23 (6.37) 8.35 (6.72) 6.84 (7.56) 1.22 (20.69 – 3.23) 1.36 (20.54 – 3.62) 0.48 (21.81 – 2.51) 0.56 (22.15 – 2.84)
CL (n=46) 18.04 (7.62) 11.83 (7.93) 11.54 (9.37) 0.81 (21.39 – 3.10) 0.77 (21.43 – 3.48) - -
Note. The standard deviations of the means and the confidence intervals of effect sizes are shown in parentheses. Intention-to-treat model was employed with pre-
treatment scores being carried forward if post-treatment or follow-up data was not available Abbreviations: GAD-7: Generalized Anxiety Disorder 7-Item; DASS-21:
Depression Anxiety Stress Scales-21 item; PSWQ: Penn State Worry Questionnaire; SIAS-6/SPS-6: Social Interaction Scale and Social Phobia Scale Short Form; PDSS-SR:
Panic Disorder Severity Scale – Self Rating; PHQ-9: Patient Health Questionnaire-9 item; SDS: Sheehan Disability Scale. CO: Coach assisted; CL Clinician assisted.
doi:10.1371/journal.pone.0028079.t005
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days of the program ending. The average number of Lessons
completed was 7.56 (SD=1.19). Post-treatment data was collected
from 38/40 (95%) Control group participants.
Post-treatment Control group results and within-group effect
sizes on primary, disorder-specific outcome measures, and
measures of depression and disability are presented in Table 4.
Paired samples t-tests revealed that the Control group achieved
significant reductions from pre- to post-treatment on all measures
(t39 range=5.06 – 9.46, all p,.000). Importantly, these analyses
were significant when adjusting for the multiple comparisons
required to examine this effect across the seven questionnaire
measures (p significance level=.007). The Control group achieved
within-group effect sizes consistent with the original CO group, on
all measures at post-treatment. Thirty-one of the 37 (84%) control
group participants who completed the post-treatment satisfaction
questionnaires reported being either very satisfied or mostly satisfied
with the program, while six (16%) participants reported being
neutral/somewhat dissatisfied with the Program, and no participants
reported feeling very dissatisfied with the program. Additionally, 36/
37 (97%) participants said they would feel confident in
recommending the program to a friend.
Discussion
This trial examined the efficacy of an extended version of the
Anxiety program, a transdiagnostic iCBT program for anxiety
disorders, when guided by either a Coach or Clinician. At intake
all participants met DSM-IV diagnosis for generalized anxiety
disorder, social phobia, or panic disorder (with or without
agoraphobia) and 70% met criteria for at least one additional
disorder.
Is a transdiagnostic iCBT program for anxiety disorders
efficacious?
Outcomes for the pooled treatment groups (CL+CO) were
superior to the Control group on all measures and this was
associated with large between-group effect sizes, with the
exception of the SDS where a moderate effect size was obtained.
Follow-up data indicated treatment effects were maintained. At
follow-up more than half the CL+CO group did not meet criteria
for their principal diagnosis. Adherence and satisfaction with
treatment was high, suggesting that transdiagnostic approaches are
acceptable to consumers. Importantly, these results were obtained
with less than 70 min of total Clinician or Coach time per
participant, and appear consistent with outcomes achieved in the
low intensity treatments offered in recent field trials of the UK
based Improved Access to Psychological Therapy program [4].
Does the program result in change in each specific
disorder?
Significant reductions were found on the corresponding
disorder-specific outcome measure for participants with each of
the three principal diagnoses. Within-group effect sizes for each of
the target disorders on their corresponding disorder-specific
measure were large and gains were maintained at follow-up.
Participants also achieved significant reductions on disorder-
specific measures different to their principal diagnosis.
Can good clinical outcomes be obtained when support is
provided by a Coach?
With one exception, no significant differences were found
between the CL and CO groups at post-treatment, the exception
being a lower GAD-7 score in the CO group. At follow-up the CO
Table 6. Means, standard deviations and effect sizes (Cohen’s d) for pooled CL+CO group on disorder specific outcome measures
at pre-treatment, post-treatment and 3-month follow-up timepoints.
Measure and Principal
diagnosis Timepoint Within group effect size
n
Pre-treatment
Mean
Post-treatment
Mean
Follow-up
Mean
Pre- to post-
treatment
Pre-treatment to
follow-up
PSWQ
Total 89 63.63 (11.01) 52.07 (10.70) 52.06 (13.37) 1.07 (21.22 –3.29) 0.95 (21.34 – 3.73)
GAD 39 67.38 (10.43) 54.77 (10.23) 54.44 (13.08) 1.24 (22.04 – 4.45) 1.11 (22.17 – 5.21)
SP 30 58.73 (11.22) 47.57 (10.70) 48.20 (11.64) 1.04 (22.98 – 4.86) 0.94 (23.08 – 5.10)
Pan/Ag 20 63.65 (9.21) 53.55 (9.82) 53.20 (15.58) 1.09 (22.95 – 5.39) 0.84 (23.20 –7.67)
SIAS-6/SPS-6
Total 89 20.31 (11.45) 12.56 (9.03) 13.26 (10.53) 0.76 (21.62 – 2.63) 0.64 (21.73 – 2.83)
GAD 39 17.85 (11.32) 10.79 (9.28) 10.92 (9.92) 0.69 (22.86 –3.60) 0.66 (22.89 – 3.77)
SP 30 25.10 (10.29) 15.97 (8.52) 15.73 (9.48) 0.98 (22.70 – 4.03) 0.96 (22.72 – 4.36)
Pan/Ag 20 17.95 (11.61) 10.90 (8.17) 14.10 (12.59) 0.72 (24.37 – 4.30) 0.33 (24.76 – 5.84)
PDSS-SR
Total 89 10.20 (6.89) 5.71 (5.80) 5.97 (7.31) 0.71 (20.72 – 1.91) 0.60 (20.83 – 2.12)
GAD 39 8.97 (6.79) 5.38 (5.27) 4.77 (6.80) 0.60 (21.53 – 2.25) 0.63 (21.50 – 2.76)
SP 30 7.90 (5.27) 3.87 (4.57) 4.00 (4.79) 0.83 (21.05 – 2.47) 0.79 (21.10 – 2.50)
Pan/Ag 20 16.05 (6.13) 9.10 (7.13) 11.25 (9.03) 1.07 (21.61 – 4.20) 0.64 (22.05 – 4.60)
Note. The standard deviations of the means and the confidence intervals of effect sizes are shown in parentheses. Intention-to-treat model was employed with pre-
treatment scores being carried forward if post-treatment or follow-up data was not available Abbreviations: PSWQ: Penn State Worry Questionnaire; SIAS-6/SPS-6: Social
Interaction Scale and Social Phobia Scale Short Form; PDSS-SR: Panic Disorder Severity Scale – Self Rating.
doi:10.1371/journal.pone.0028079.t006
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in the CL group on the GAD-7, PDSS-SR, and SDS. These
results were unanticipated, and require replication. As a partial
replication, the Control group received the CO treatment and
achieved post-treatment outcomes comparable to those obtained
by the original CO group. This result is consistent with studies
indicating that non-clinical support roles for guided and highly
structured iCBT programs for common mental disorders are
associated with good clinical outcomes [9,11,49].
Limitations
Limitations of the present study are relevant to other studies in
the field of transdiagnostic treatment. We had sufficient power to
detectmediumtolargedifferencesbetweengroups,butnottodetect
small differences between groups or to compare between groups
based on principal diagnosis. Consequently, small differences
between groups could exist that were not detected in the present
study, and which future studies employing larger sample sizes may
reveal. It is important to note that the sample sizes required to
address these issues are considerable, and was only able to be
approximated by pooling treatment data. Pragmatic approaches
such as those used here may provide a practical and preliminary
alternative for answering such important questions; however, more
expansive research is required. Future research employing larger
samples may benefit from considering mixed models approaches
that will further inform the debate surrounding treatment response.
A second limitation concerns the choice of general and disorder
specific outcome measures; an issue identified in the broader field
of transdiagnostic research [16]. In the present study we selected
brief measures to reduce burden on participants. There is a need
for broader discussion regarding the questionnaire batteries most
appropriate for the evaluation of transdiagnostic treatment and to
facilitate comparison of results.
A third limitation concerns blinding. Due to resource
constraints researchers were not blinded for 3-month follow-up
diagnostic interviews, which may have resulted in under-reporting
of diagnostic symptoms. The enduring gains made by treatment
groups across a broad range of outcome measures mitigates some
of this concern, however, future research will clearly benefit from
blinding in diagnostic interviews.
A fourth limitation concerns the generalizability of the current
findings. Independent replication is required to further understand
the relative efficacy of Clinician and Coach roles for guided iCBT.
Future studies would also benefit from comparing treatment with
an active control group rather than a delayed-treatment waiting
list. For example, the treatment gains in the present study may be
solely due to telephone contact and, although unlikely, this cannot
be ruled out using a wait-list control group. Future research
employing telephone contact as part of an active control may go
some way to informing non-specific treatment effects.
An additional limitation is the duration of follow-up analyses.
Some authors argue that transdiagnostic treatments target
underlying vulnerabilities and thus may lead to more durable
treatment effects [50]. Follow-up data in the present study is
consistent with existing research [51], yet future research would
benefit from considering longer follow-up periods.
General discussion
The findings of the current study are consistent with both the
broader transdiagnostic and iCBT literature. Improvements on
the general measures of anxiety are consistent with meta-analyses
of transdiagnostic face-to-face programs for the anxiety disorders
[52]. Analyses by principal disorder indicated improvement on the
relevant diagnosis-specific outcome measures and also on
diagnosis-specific measures different to the principal diagnosis.
This supports the argument that transdiagnostic treatments may
help consumers generalise beyond their principal complaint [16].
The magnitude of treatment gains in the present study are also
comparable with those reported in meta-analyses of Internet and
computer-aided psychotherapy for symptoms of anxiety [7]. Analyses
by principal disorder yielded results consistent with those reported in
recent studies of disorder-specific iCBT programs for GAD [53], SP
[54] and Pan/Ag [46]. The outcomes achieved by the CO group,
which were partially replicated with the Control group, are consistent
with research indicating that coaching and clinical support roles can
result in similar outcomes for guided iCBT [9,45].
The Control group in the present research provided a partial
replication of the CO condition, but independent replication of the
study is required to examine the reliability of the findings. Future
research examining the role of comorbidity and consumer attitudes,
are two areas of research that will inform discussion regarding
transdiagnostic treatment and are the topic of studies currently
underway. Future research exploring the relative efficacy of
transdiagnostic and individually-tailored interventions would be of
value, as both approaches have provided encouraging findings
regarding disorder specific change and have potential for the
treatment of comorbidity [25,55]. Additionally, future studies using
a larger sample size would allow comparison of transdiagnostic iCBT
with disorder-specific iCBT, and would begin to inform the debate
around the relative utility of these approaches. An unresolved tension
in the field of transdiagnostic treatment concerns the suitability of
disorders such as OCD and PTSD to this approach [17], and
inclusion of a broader range of disorders is required for future
research to begin answering these questions. Moreover, research
examining the relative benefits of clinician and coaching guidance in
non-research environments is required to inform discussion about the
dissemination of low-intensity interventions [5,56].
Conclusions
This is an extension of a transdiagnostic iCBT program for three
anxiety disorders. This randomized controlled trial revealed overall
outcomes that were superior for the treatment groups relative to a
waitlist control condition and which were stable over a 3 month follow
up period and satisfactory to participants. Outcomes by principal
diagnosis appeared consistent with those obtained in disorder-specific
iCBT programs, and allowed participants to generalise gains beyond
symptoms of their principal complaint. Coach assisted iCBT was as
effective as Clinician assisted iCBT. Further studies need to explore
questions about the role of comorbidity, consumer attitudes, to
investigate clinical and coaching support roles and the relative efficacy
of transdiagnostic and disorder-specific iCBT.
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